NCT06576973 2025-12-02
Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
Clinical Trials
10 trialsNCT06281886 2025-11-17
Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06339619 2024-04-01
Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT02976896 2023-02-16
Poetry-1
Sun Yat-sen University
Phase 2 Completed
NCT03251417 2023-02-01
Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Terminated
NCT02645864 2021-03-18
Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma
Peking University
Phase 1 Completed
NCT03603756 2020-02-11
SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer
ChineseAMS
Phase 2 Unknown
NCT03913182 2020-02-05
Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer
Shanghai Chest Hospital
Phase 2 Unknown
NCT03857763 2019-02-28
A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma
Hebei Medical University Fourth Hospital
Phase 2 Unknown
NCT03224221 2017-07-21
Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment
The First Affiliated Hospital of Anhui Medical University
Phase 2 Unknown